pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TARSUS · news · pharmadog
← back to TARSUS
News mentioning TARSUS
9
stories
6d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
Oct 1, 26
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
biospace
Sep 24, 26
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
Sep 17, 26
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
fiercebiotech
Aug 6, 26
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
biopharma dive
Aug 6, 26
Tarsus bets $450M on Alkeus’ Stargardt drug
endpoints
Aug 6, 26
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
fiercebiotech
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jul 9, 26
Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
endpoints
